In CCM‐deficient cells, ICAP‐1, an inhibitor of β1‐integrin activation, becomes targeted for proteasome degradation, thereby exacerbating integrin signaling and augmenting RhoA‐dependent cytoskeletal tension (Faurobert et al. 2013). This evidence concerns the gene RHOA and cerebral cavernous malformation.